| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2810895 | Trends in Endocrinology & Metabolism | 2006 | 5 Pages |
Abstract
Mifepristone is a potent glucocorticoid and progesterone receptor antagonist. The pathophysiology of a number of neuropsychiatric disorders implicates abnormalities in glucocorticoid function. These include mood disorders such as psychotic major depression and bipolar depression. In addition, cognitive disorders such as Alzheimer's disease might also be partially mediated by abnormalities in the hypothalamic–pituitary–adrenal axis. Preliminary studies suggest that mifepristone might have a role in the treatment of a number of neuropsychiatric disorders.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Charles DeBattista, Joseph Belanoff,